Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995.

Hoeldtke RD, O'Dorisio TM, Boden G

Lancet (London, England)1 Sept 1986Cited by 57 (Europe PMC)

PMID2875321DOI10.1016/s0140-6736(86)92428-1PepBankPUB-02875321

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
SMS-201-995 raised upright postprandial blood pressure in five of seven patients with hypotension.
In plain wordsSMS-201-995 raised upright blood pressure after meals in five of seven patients.
Peptide
Octreotide
Outcome
IncreaseUpright postprandial blood pressure
Study
n = 7
Outcome group
Blood pressure · Cardiovascular
Studied dose
up to 1.6 micrograms/kgAs given in this study (human).
Measurements
Patients with raised upright postprandial blood pressure
5 patients
doses up to 1.6 micrograms/kg
Source sentences
Summary
Larger doses (up to 1.6 micrograms/kg) raised upright blood pressure during the postprandial period in five of seven patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532103
02HumanNon-randomized trialEfficacy outcome
In patients with postprandial hypotension, SMS-201-995 raised blood pressure after breakfast in all six patients.
In plain wordsSMS-201-995 raised blood pressure after breakfast in all six patients with postprandial hypotension.
Peptide
Octreotide
Outcome
IncreasePostprandial blood pressure
Study
n = 6
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.2-0.4 microgram/kgAs given in this study (human).
Measurements
Patients with raised postprandial blood pressure
6 patients
postprandial hypotension, 0.2-0.4 microgram/kg
Source sentences
Summary
Low doses of this drug (0.2-0.4 microgram/kg) raised the blood pressure after breakfast in all six patients with postprandial hypotension.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532101
03HumanNon-randomized trialEfficacy outcome
Three patients unable to stand after eating could walk for 35-100 min after SMS-201-995 at breakfast.
In plain wordsThree patients unable to stand after eating could walk for 35-100 min after SMS-201-995.
Peptide
Octreotide
Outcome
IncreaseAbility to walk after breakfast
Study
n = 3
Comparator
Before therapy
Outcome group
Exercise and physical function · Whole body
Studied dose
0.8 microgram/kg · injectionAs given in this study (human).
Measurements
Walking duration
35 to 100 min
after injection
Source sentences
Summary
Before therapy three patients were unable to stand after eating; after an injection of SMS-201-995 0.8 microgram/kg at the beginning of breakfast they were able to walk for 35-100 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532104
04HumanNon-randomized trialEfficacy outcome
In patients with hypotension, sitting blood pressure after SMS-201-995 exceeded placebo by 35 +/- 10 mm Hg at 60 min after breakfast.
In plain wordsIn patients with hypotension, SMS-201-995 raised sitting blood pressure more than placebo after breakfast.
Peptide
Octreotide
Outcome
IncreaseSitting blood pressure after breakfast
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.4 microgram/kgAs given in this study (human).
Measurements
Blood pressure difference
35 mm Hg
60 min after breakfast versus placebo
SEM
10 mm Hg
blood pressure difference
P value
< 0.001
versus placebo
Source sentences
Summary
60 min after breakfast the mean sitting blood pressure was 35 +/- 10 (SEM) mm Hg higher after administration of SMS-201-995 0.4 microgram/kg than after placebo (p less than 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532102
05HumanNon-randomized trialEfficacy outcome
In patients with hypotension, each SMS-201-995 injection had a therapeutic effect lasting 3-6 h.
In plain wordsIn patients with hypotension, each SMS-201-995 injection acted for 3-6 h.
Peptide
Octreotide
Outcome
Not applicableDuration of therapeutic effect
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · injectionAs given in this study (human).
Measurements
Therapeutic effect duration
3 to 6 h
each injection
Source sentences
Summary
The duration of therapeutic effect of each injection was 3-6 h.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532105
06HumanNon-randomized trialSafety outcome
Two patients with gastroparesis diabeticorum experienced abdominal cramps after SMS-201-995 treatment.
In plain wordsTwo patients with diabetic gastroparesis experienced abdominal cramps after SMS-201-995 treatment.
Peptide
Octreotide
Outcome
Direction not reportedAbdominal cramps
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Patients with abdominal cramps
2 patients
patients with gastroparesis diabeticorum
Source sentences
Summary
Treatment was followed by abdominal cramps and nausea in two patients with gastroparesis diabeticorum.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532106
07HumanNon-randomized trialSafety outcome
Two patients with gastroparesis diabeticorum experienced nausea after SMS-201-995 treatment.
In plain wordsTwo patients with diabetic gastroparesis experienced nausea after SMS-201-995 treatment.
Peptide
Octreotide
Outcome
Direction not reportedNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Patients with nausea
2 patients
patients with gastroparesis diabeticorum
Source sentences
Summary
Treatment was followed by abdominal cramps and nausea in two patients with gastroparesis diabeticorum.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995.
Report a problemFND-0287532107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.